Related Experiment Video

Updated: Apr 20, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.8K

[Evaluation of six cases of arbekacin inhalation for pneumonia]

Yukihiro Hamada, Hiroyuki Suematsu, Jun Hirai

    The Japanese Journal of Antibiotics
    |November 26, 2014
    PubMed

    Insights

    Arbekacin inhalation effectively treated pneumonia in six patients with multidrug-resistant organisms. This approach may benefit cases where standard treatments fail or intravenous access is limited.

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Pulmonology

    Background:

    • Arbekacin (ABK) is an aminoglycoside antibiotic effective against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative bacteria (GNB).
    • ABK demonstrates potential efficacy against antimicrobial-resistant GNB.
    • Pulmonary drug delivery via inhalation offers a promising route for treating respiratory infections.

    Purpose of the Study:

    • To investigate the efficacy of Arbekacin (ABK) inhalation therapy for pneumonia caused by multidrug-resistant Gram-negative organisms and MRSA.
    • To assess the clinical outcomes of ABK inhalation in patients with severe pneumonia.

    Main Methods:

    • A cohort of six patients with pneumonia received Arbekacin inhalation therapy at a dosage of 50 mg three times daily.
    • Clinical effects were observed and documented for all treated patients.

    Main Results:

    • All six patients (6/6) showed a clinical effect from the Arbekacin inhalation therapy.
    • The treatment was effective against multidrug-resistant organisms causing pneumonia.

    Conclusions:

    • Arbekacin inhalation therapy demonstrated clinical efficacy in treating pneumonia caused by multidrug-resistant organisms.
    • This therapy may be a viable option for specific pneumonia cases, particularly when systemic therapy is inadequate or intravenous access is challenging.
    • Further research is warranted to establish the role of ABK inhalation for pneumonia treatment.

    More Related Videos

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

    Published on: January 2, 2017

    15.4K
    P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives10:26

    P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

    Published on: June 15, 2020

    12.0K

    Related Concept Videos

    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    1.1K
    Atypical Pneumonia01:14

    Atypical Pneumonia

    Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
    72
    Pneumonia III: Complications and Assessment01:30

    Pneumonia III: Complications and Assessment

    Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
    1.3K
    Pulmonary Tuberculosis IV01:26

    Pulmonary Tuberculosis IV

    Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
    Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
    768
    Assessment of Respiration01:23

    Assessment of Respiration

    The respiratory system's basic structures and primary functions lay the foundation for nurses' comprehensive respiratory assessments. This assessment includes subjective and objective data to gauge the patient's respiratory health.
    Subjective Assessment: Nurses interview the patient to gather information directly during the subjective assessment. It includes questions about the individual's medical history, medications, and symptoms, focusing on past respiratory conditions like...
    2.5K
    Pneumonia I: Introduction01:29

    Pneumonia I: Introduction

    Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
    16